Today’s top gainers include the company Mylan N.V. (NASDAQ:MYL) which is in the industry Drugs – Generic, gaining 2.61% today. In the last week its performance is -2.40%, and -20.78% for the past quarter. Currently, Mylan N.V., MYL has a target price of 53.83, so today’s gain of 2.61% is a significant step towards its target price. The GAP today is therefore 1.40%.
Mylan N.V. (NASDAQ:MYL), has a market cap of 20762.29, and is based in USA. Insider ownership is at 0.20%, and institutional ownership is 64.70%.
At the current price of 37.39, it has a dividend yield of *TBA, and its target price is 53.83. This is with a profit margin of 8.10%, and total debt/equity of 1.31. Mylan N.V. (NASDAQ:MYL) has a P/E of 23.77, as well as a forward P/E of 6.7.
With a current EPS of 1.57, and a forecasted EPS growth for next year at 16.48%,Mylan N.V. (NASDAQ:MYL) has had a EPS growth for the past five years at 20.20%. For the next five years EPS growth is projected to be 13.04%.
Performance for the year is -14.52%. Since its IPO date on 12/18/1987, the total performance to date is -30.85%.
Volume today for Mylan N.V. (NASDAQ:MYL), is 5780300, while its average volume is 6821.35. Whilst the total gain today was 2.61%, it did have a day high of -25.81%.
Volatility for this week has been at 3.33%, and 3.04% for the month. The 52-week low for Mylan N.V., MYL has been 5.09%, while the 52-week-high has reached -32.64%.
Looking at its return of investments, which is 8.20%, and its return on assets is 3.40%. Mylan N.V. (NASDAQ:MYL) has an operating margin of 15.70%. With a sales growth of 8.00% quarter over quarter. Bearing in mind that Mylan N.V., MYL is in the sector Healthcare, its long-term debt/equity is 1.24, and has a current ratio of 3.2 and 2.6 for quick ratio.
So what is the value of Mylan N.V.? Well its PEG is 1.82, and the P/S is 2.09, along with a P/B of 1.83. Meanwhile it has a p/cash of 3.26.